<form id="r15xh"></form>

<address id="r15xh"><dfn id="r15xh"><ins id="r15xh"></ins></dfn></address>

<thead id="r15xh"><var id="r15xh"></var></thead>

<sub id="r15xh"><dfn id="r15xh"></dfn></sub>

    <sub id="r15xh"></sub>


      roductsand services

      Innovative Drugs

      Home > Products & services > Innovative Drugs

      SPN003 / SPN004

      Candidate drug screening is going to be completed.

      SPN003/SPN004 are  innovative peptide drugs with synergistic effect on target,  with metabolic diseases including type 2 diabetes and obesity as the main indications.


      Candidate drug screening  has been completed, preclinical studies  are under way.

      SPN007 is a new polypeptide drug with proprietary intellectual property rights. Its indications have expanded from simply lowering blood glucose levels in type 2 diabetes to treating obesity and non-alcoholic fatty liver disease (NASH).


      At the stage of preclinical studies.

      Spn009 is an innovative long-acting hypoglycemic drug  for type 2 diabetes mellitus.


      At the stage of candidate drug screening.

      SPN-X is a peptide inhibitor against the novel coronavirus main protease.

      Mobile version


      Sales Department: